The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants

BACKGROUND AND OBJECTIVE: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the second-line treatment of patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Lorlatinib is metabolized by cytochrome P450 (CYP) 3A and contraindicated with strong...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jerry, Pithavala, Yazdi K., Gong, Jason, LaBadie, Robert R., Mfopou, Josué Kunjom, Chen, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505275/
https://www.ncbi.nlm.nih.gov/pubmed/33937953
http://dx.doi.org/10.1007/s40262-021-01026-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505275/
https://www.ncbi.nlm.nih.gov/pubmed/33937953
http://dx.doi.org/10.1007/s40262-021-01026-w

Ejemplares similares